in a news release, the drug's manufacturer, amgen, said the list price will be 5 a month or ,900 annually. costs to patients may vary depending on insurance.
.
eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention.
.
. "the importance of our new method is that it allows for precise and automated measurement of the disease," bentley added in the study published in the journal radiology.
.
edition
international editions:
.
.arabic
.
$17
OFFDEAL
Birthday Collections From $17 @ Cosmetics Promo Codes